ArticleHealthcare (Basel, Switzerland)2021
Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic.
Article in Healthcare (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Outcomes of Micropulse Transscleral Cyclophotocoagulation in Primary Open-Angle and Pseudoexfoliative Glaucoma.Medicina (Kaunas, Lithuania) · 2026Article
- The efficacy of MicroPulse Transscleral Laser Therapy as primary surgical treatment in various types of glaucoma resistant to medical treatment: a retrospective analysis.BMC ophthalmology · 2026Article
- Development and Novel Therapeutics in Diabetic Retinopathy.Current diabetes reviews · 2026Review
- Intraocular pressure changes and pain scores within 24 hours and short-term outcomes after micropulse transscleral laser therapy.PloS one · 2026Article
- MicroPulse Transscleral Cyclophotocoagulation for Early to Moderate Glaucoma: A Case Series of 11 Eyes with One-Year Follow-Up and Literature Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- The effect of cumulative energy in repeated subliminal transscleral cyclophotocoagulation: a retrospective study.BMC ophthalmology · 2024Article
- Scleral burn and perforation following transscleral cyclophotocoagulation.American journal of ophthalmology case reports · 2023Article
- Assessment of Pain in Glaucoma Patients Undergoing Micropulse Transscleral Laser Therapy.Journal of clinical medicine · 2023Article
- Postoperative Pain after Different Transscleral Laser Cyclophotocoagulation Procedures.International journal of environmental research and public health · 2023Article
- Impact of COVID-19 on glaucoma management: A review.Frontiers in ophthalmology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is the leading cause of irreversible blindness worldwide, with primary open angle glaucoma (POAG) accounting for the greatest number of total glaucoma cases. This study aimed to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) as a primary procedure in POAG during the COVID-19 pandemic. We retrospectively analyzed 60 eyes of 52 patients, who were diagnosed with mild-to-end-stage POAG without previous glaucoma surgery and received MP-TSCPC between 1 January 2020 and 31 August 2020. The mean preoperative intraocular pressure (IOP) significantly decreased from 27.8 mm Hg to 19.8, 20.1, 20.3, 20.4, and 20.2 mm Hg at 1, 3, 6, 9, and 12 months, respectively (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.